Young SC, Storm MV, Speed JS, Kelsen S, Tiller CV, Vera T, Drummond HA, Stec DE. Inhibition of biliverdin reductase increases ANG II-dependent superoxide levels in cultured renal tubular epithelial cells. Am J Physiol Regul Integr Comp Physiol 297: R1546 -R1553, 2009. First published September 16, 2009 doi:10.1152/ajpregu.90933.2008.-Induction of heme oxygenase-1 (HO-1) in the renal medulla increases carbon monoxide and bilirubin production and decreases ANG II-mediated superoxide production. The goal of this study was to determine the importance of increases in bilirubin to the antioxidant effects of HO-1 induction in cultured mouse thick ascending loop of Henle (TALH) and inner medullary collecting duct (IMCD3) cells. Bilirubin levels were decreased by using small interfering RNAs (siRNAs) targeted to biliverdin reductase (BVR), which is the cellular enzyme responsible for the conversion of biliverdin to bilirubin. Treatment of cultured TALH or IMCD-3 cells with BVR siRNA (50 or 100 nM) resulted in an 80% decrease in the level of BVR protein and decreased cellular bilirubin levels from 46 Ϯ 5 to 23 Ϯ 4 nM (n ϭ 4). We then determined the effects of inhibition of BVR on ANG II-mediated superoxide production. Superoxide production induced by ANG II (10 Ϫ9 M) significantly increased in both TALH and IMCD-3 cells. Treatment of TALH cells with BVR siRNA resulted in a significant increase in ouabain-sensitive rubidium uptake from 95 Ϯ 6 to 122 Ϯ 5% control (n ϭ 4, P Ͻ 0.05). Lastly, inhibition of BVR with siRNA did not prevent the decrease in superoxide levels observed in cells pretreated with the HO-1 inducer, hemin. We conclude that decreased levels of cellular bilirubin increase ANG II-mediated superoxide production and sodium transport; however, increases in bilirubin are not necessary for HO-1 induction to attenuate ANG II-mediated superoxide production.
REACTIVE OXYGEN SPECIES SUCH as superoxide anion are generated as a normal part of cellular metabolism. Superoxide anion is also generated directly by NAD(P)H oxidase, whose activity can be enhanced by several hormones and peptides, such as ANG II (7, 14) . To buffer against increases in superoxide anion production and other reactive oxygen species, cells have evolved several endogenous antioxidant systems, including glutathione peroxidase, superoxide dismutase, catalase, and bilirubin.
Bilirubin is generated via the intracellular breakdown of heme via heme oxygenase (HO) (1) . Heme is broken down into carbon monoxide (CO) gas, iron, and biliverdin. Biliverdin is then converted into bilirubin via the actions of biliverdin reductase (BVR) (1) . Bilirubin is a potent cellular antioxidant that not only is able to directly scavenge superoxide anion but can also directly inhibit NAD(P)H oxidase (11, 19) .
We have previously demonstrated that induction of HO-1 or increases in CO or bilirubin alone can attenuate ANG IImediated superoxide production in mouse thick ascending loop of Henle (TALH) cells (9) . However, it is difficult to determine the relative importance of increases in endogenous CO or bilirubin to the antioxidant effect of HO-1 induction. In the present study, we used a small interfering RNA (siRNA) approach to specifically decrease BVR protein levels and decrease the levels of bilirubin in both mTALH and inner medullary collecting duct (IMCD3) cells. We then determined the effect of reduced intracellular bilirubin generation on ANG II-mediated superoxide production and sodium transport. Lastly, we determined whether decreases in BVR activity alter the antioxidant actions of HO-1 induction in TALH and IMCD3 cells.
METHODS

Cell culture. Mouse thick ascending loop of Henle cells (mTALH)
were derived from those originally described by Wolf et al. (24) and kindly provided by Dr. Christopher Y. Lu. mTALH cells were grown and maintained in a medium consisting of 89% DMEM, 10% FBS, and a 1% penicillin/streptomycin (Penn/Strep) antibiotic. Serum-free media were used in all experiments. The serum-free media consisted of 98.6% DMEM, 0.4% FBS, and 1% Pen/Strep. Mouse inner medullary collecting duct cells (IMCD3) were obtained from American Type Culture Collection (Manassas, VA) and grown in a medium consisting of 89% DMEM:F12 (1:1), 10% FBS, and 1% Pen/Strep. Serum-free media used in all experiments consisted of 98.6% DMEM: F12K, 0.4% FBS, and 1% Pen/Strep. The cells were incubated at 37°C and used when they reached 70 -80% confluence. Cells were grown on collagen-coated eight-well glass slides at a density of 20,000 cells/well.
In all experiments, cells were incubated in serum-free media for 12 h before addition of ANG II (10 Ϫ9 M; Bachem, King of Prussia, PA). ANG II was added to cells 48 h after transfection for 1 h at 37°C. Some experiments were performed after cells had been incubated with the HO-1 inducer, hemin (50 M). Hemin was added to the cells 24 h after transfection for 16 h, after which time it was removed and ANG II was immediately added to the cells for 1 h at 37°C. After the 1 h ANG II incubation, cells were processed for dihydroethidium staining, as described below.
Transfection with BVR siRNA. siRNA directed against mouse BVR-A consisted of a mixed pool of siRNA purchased from a commercial source (ON-TARGETplus SMARTpool; Dharmacon, Chicago, IL). As a control, a nontargeting (NT), RISC (RNAi silencing complex) activating, siRNA was used (Nontargeting siRNA #2, Dharmacon). siRNAs were resuspended as 20-M stock solutions, according to manufacturer's guidelines. Transfection was performed using Lipofectamine LTX reagent (Invitrogen, Carlsbad, CA) diluted in Opti-MEM media, according to manufacturer's protocol. Cells were incubated with siRNA for 4 h at 37°C after which time the siRNA/Opti-MEM media were removed and replaced with growth media. Cells were used in experiments 48 h after transfection.
Dihydroethidium (DHE) staining and lucigenin assay. DHE staining was performed as previously described (9) . Briefly, DHE (5 M, Molecular Probes, Eugene, OR) was added to cells seeded on 8-well collagen-coated glass slides. Slides were then incubated at 37°C for 30 min in the dark. The cells were then fixed in formaldehyde and mounted, and a coverslip was placed over the slide. DHE fluorescence was measured using confocal microscopy. Confocal microscopy was performed on a Leica TCS SP2 laser-scanning confocal microscope (Leica Microsystems, Exton, PA). Fluorescence was measured at excitation of 488 nm with emission at 560 nm and 590 nm, as described previously (28) . Data were collected from 50 cells obtained from 5 random fields using a 40ϫ objective. Fluorescence intensity between 560 and 590 nm was then normalized for cell size and analyzed as fluorescence intensity (FI)/ cell area (m 2 ). Superoxide levels were also measured using lucigenin-enhanced chemiluminescence assay, as described previously (27) . Cells were grown on 60-mm plastic petri dishes and transfected with nontargeting or biliverdin reductase siRNA as described above. Forty-eight hours after transfection, cells were incubated overnight in reduced serum (0.4%) media with or without biliverdin (50 M). The next day, cells were trypsinized and suspended in 1 ml of HEPES buffer. ANG II (10 Ϫ9 M) and lucigenin (5 M) were then added to each of the samples, which were then placed in 1.6-ml polypropylene 8 ϫ 50-mm tubes (Evergreen Scientific). After allowing the samples to equilibrate with both ANG II and lucigenin at 37°C for 30 min, we placed the tubes in a luminometer (TD-20e; Turner Designs, Sunnyvale, CA) with the light chamber maintained at 37°C. Luminescence measurements were integrated for 30-s periods, and the cycle repeated 9 times, averaging 10 values. At the end of each experiment, the protein concentration of the samples was measured using a modification of the Bradford method. Superoxide levels are presented as the relative light units per mg protein expressed as a percentage of control cells not receiving ANG II. For experiments in which cells were pretreated with biliverdin, superoxide levels were expressed as a percentage of lucigenin activity observed in cells treated with ANG II alone.
Measurement of cellular bilirubin. The levels of cellular bilirubin were measured following incubation of cells with biliverdin (100 M) for 6 h at 37°C. Cell lysates were prepared from cells grown on 100-mm plastic dishes. Cells were lysed in a PBS by brief (5 s) sonication and centrifuged at 3,000 g for 10 min at 4°C. An equal volume of chloroform was then added to the supernatant. The samples were then thoroughly mixed and stored at Ϫ20°C overnight. Samples were then thawed and centrifuged at 15,000 g for 5 min at 4°C. The organic fraction (bottom layer) was then collected, and the absorbance was measured at 464 nm and 530 nm using an extinction coefficient of 40 mM/cm for bilirubin and expressed as nanomoles/liter.
Measurement of BVR activity. BVR activity was measured in TALH cells plated in 60-mm plastic dishes. Cells were transfected with nontargeting or BVR siRNA, as described above. Hemin (50 M) was added to cells as described above. BVR activity was measured in pooled samples of cells (three dishes per sample, three samples per group) using a colorimetric reaction to measure the formation of bilirubin, as described by manufacturer (Sigma, St. Louis, MO). Cells were lysed in 150 l of extraction buffer, and the assay was performed using 150 g of total protein. Bilirubin levels were measured at 450 nm at 37°C 18 min after start of the reaction. BVR activity was expressed as units/ml with 1 unit of biliverdin reductase converting 1 nanomole of biliverdin to bilirubin in an NADPH-dependent fashion at pH 8.5 at 37°C.
Western blot analysis. Western blots were performed on cell lysates from cells grown in 100-mm dishes. Cells were transfected as described above. Samples of 30 g of protein were boiled in Laemmli sample buffer (Bio-Rad, Hercules, CA) for 5 min and electrophoresed on 7.5% SDS-polyacrylamide gels and blotted onto nitrocellulose membrane. Membranes were blocked with Odyssey blocking buffer (Li-COR, Lincoln, NE) for 2 h at room temperature, then incubated with rabbit anti-BVR polyclonal antibody (1:2,000, StressGen, Vancouver, Canada), as well as a mouse anti-␤-actin antibody (1:5,000 BD Gentest, San Jose, CA) overnight at 4°C. The protein levels of manganese (Mn) and copper-zinc (CuZn) SOD were measured with a polyclonal antibody (1:1,000; StressGen) and were used in conjunction with mouse anti-␤-actin antibody. Catalase protein was detected using a monoclonal antibody (1:10,000; Sigma) in conjunction with a rabbit anti-␤-actin antibody. The membranes were then incubated with Alex 680 conjugated goat anti-mouse IgG (1:2,000; Molecular Probes, Eugene, OR) and IRDye 800 conjugated goat anti-rabbit IgG (1:2,000; Rockland, Gilbertsville, PA) for 1 h at room temperature. The membranes were then visualized using an Odyssey infrared imager (Li-COR), which allows for the simultaneous detection of two proteins. Analysis of fluorescence was performed using Odyssey software (Li-COR). Levels of protein are expressed as the ratio to ␤-actin for each sample.
Immunofluorescence. Cells were seeded on 8-well collagencoated glass slides and transfected with BVR, as described above and incubated at 37°C for 48 h following transfection. After this time, cells were fixed in 4% paraformaldehyde for 10 min and rinsed in PBS. Cells were then blocked in 5% normal donkey serum (NDS) for 1 h at room temperature. Samples were then incubated with primary antibody rabbit anti-BVR (1:200; StressGen) in 5% NDS overnight at 4°C, then rinsed in PBS. Samples were incubated with Cy3-conjugated donkey anti-rabbit (1:100; Jackson Immunologicals, West Grove, PA) for 1 h at 37°C in 5% NDS. Following a final rinse in PBS, samples were covered with Gel Mount mounting media and coverslipped. Antibody localization was visualized using confocal microscopy (Leica TCS SP2). All samples were collected, immunolabeled, and imaged side-byside under identical conditions.
86 Rb ϩ uptake in TALH cells. Ouabain-sensitive 86 Rb ϩ uptake was performed in TALH cells as previously described (26) . Briefly, cells were grown on 60-mm plastic petri dishes and transfected with nontargeting or BVR siRNA, as described above. After 48 h, cells were trypsinized, pooled, and suspended in 3 ml of PBS. 86 Rb ϩ uptake was performed in 100-l aliquots of TALH cells (ϳ250,000). Cells were treated with nothing (control) or ANG II (10 Ϫ9 M) or ouabain (2 mM). After treatment, cells were incubated at 37°C for 15 min in the presence of 100% O 2. After this time, 86 Rb ϩ (0.2 Ci) was added to the cell suspension and incubated for 5 min at 37°C in the presence of 100% O 2.
86 Rb ϩ uptake was terminated by adding 300 l of an ice-cold stop solution containing (in mM) 150 NaCl, 10 BaCl2, and 10 HEPES. The cells were then briefly centrifuged at 3,000 g and 300 l of a mixture of dioctyl phthalate and silicone oil (1.75:1) was then added. Cells were then centrifuged at 10,000 g for 3 min. After discarding the supernatant, the bottom of the tube containing the cell pellet was cut off into a scintillation vial, and the 86 Rb ϩ activity in the pellet was determined using a gamma counter. Protein concentration was determined in a separate aliquot of cells using a modified Bradford method to normalize uptake per milligram of protein. 86 Rb ϩ uptake assays were performed in triplicate and were repeated four different times. Subtraction of the 86 Rb ϩ uptake in the presence and absence of ouabain provided the estimate of Na ϩ transport. Data are presented as the average of the percentage of Na ϩ transport exhibited after siRNA treatment compared with control cells.
Statistics. Mean values Ϯ SE are presented. Significant differences between mean values were determined with the use of an ANOVA followed by a post hoc test (Dunnett's). A P Ͻ 0.05 was considered to be significant.
RESULTS
Targeting of BVR with siRNA in mouse TALH and IMCD3 cells.
To decrease endogenous levels of BVR in TALH and IMCD3 cells, we used a mixed pool of siRNAs generated against mouse BVR-A isoform. Knockdown was evaluated by examining the levels of BVR protein with Western blot and immunohistochemistry. Treatment of mouse TALH cells with BVR siRNA at either 50 or 100 nM resulted in a decrease in BVR protein by 80% compared with untreated and cells treated with a nontargeting (NT) siRNA (Fig. 1A) . Similar effects were observed in mouse IMCD3 cells (Fig. 1B) . Levels of BVR protein were also evaluated by immunofluorescence in mouse IMCD3 cells treated with 50 nM BVR siRNA. siRNA treatment resulted in a significant decrease in BVR immunofluorescence 48 h after transfection (Fig. 1C ). These results demonstrate that treatment with BVR siRNA significantly decreased BVR protein levels 48 h after transfection.
BVR siRNA reduces cellular bilirubin generation. Experiments were then performed to evaluate the effect of knockdown of BVR on bilirubin generation in mouse TALH cells. Bilirubin generation in response to exogenous biliverdin treatment was determined 48 h after transfection with NT or BVR siRNA. Cellular bilirubin concentration following biliverdin administration averaged 46 Ϯ 5 nM and was significantly reduced to 23 Ϯ 3 nM after treatment with BVR siRNA (Fig. 2) . Treatment with NT siRNA had no significant effect on cellular bilirubin concentration which averaged 39 Ϯ 6 nM (Fig. 2) . (Fig. 3A) . Incubation of TALH cells with NT siRNA had no significant effect on ANG II-mediated superoxide production, which averaged 49 Ϯ 6 FI/area (Fig. 3A) . Similar effects were also observed in mouse IMCD3 cells, where siRNA treatment at 50 or 100 nM significantly increased ANG II-mediated superoxide production from 36 Ϯ 6 to 60 Ϯ 6 and 71 Ϯ 5 FI/area (Fig. 3B) . Incubation of IMCD3 cells with NT siRNA had no significant effect on ANG II-mediated superoxide production which averaged 36 Ϯ 7 FI/area (Fig. 3B) . Thus, decreases in BVR result in increased ANG II-mediated superoxide production in both mouse TALH and IMCD3 cells. Treatment of TALH cells with BVR siRNA did not alter the levels of catalase, CuZn, or Mn SOD levels (data not shown). 
Biliverdin pretreatment does not decrease ANG II-mediated superoxide production in TALH cells treated with BVR siRNA.
Biliverdin can cross the cell membrane and be converted to bilirubin via BVR (3) . To determine whether exogenously added biliverdin could decrease ANG II-mediated superoxide production, we performed an experiment in which TALH cells were incubated with biliverdin prior to treatment with ANG II. In this set of experiments, superoxide production was measured using lucigenin-enhanced chemiluminescence assay. We first confirmed the effect of BVR siRNA on ANG IImediated superoxide production in TALH cells using this technique. Treatment of TALH cells with BVR siRNA resulted in a significant increase in ANG II-mediated superoxide production similar to what we observed using the DHE staining method. Superoxide production averaged 145 Ϯ 27, vs. 162 Ϯ 25, vs. 195 Ϯ 50% control in ANG II, vs. ANG II ϩ nontargeting siRNA, vs. ANG II ϩ BVR siRNA, respectively (Fig. 4A) . Pretreatment with biliverdin resulted in a significant decrease in ANG II-mediated superoxide compared with ANG II-treated alone cells averaging 75 Ϯ 9% (Fig. 4B) . Treatment with nontargeting siRNA resulted in an attenuation of the effect of biliverdin with superoxide levels averaging 94 Ϯ 12% compared with cells treated with ANG II alone (Fig. 4B) . However, treatment with BVR siRNA resulted in a nearly three-fold increase in ANG IImediated superoxide production in cells pretreated with BVR with levels averaging 276 Ϯ 50% compared with cells treated with ANG II alone (Fig. 4B) .
BVR siRNA does not increase ANG II-mediated superoxide production in hemin-treated TALH cells.
To determine the effect of BVR inhibition on the ability of HO-1 induction to attenuate ANG IImediated superoxide production, experiments were performed in which HO-1 was induced in TALH cells treated with BVR siRNA. Treatment of TALH with hemin resulted in a significant decrease in ANG II-mediated superoxide production from 32 Ϯ 4 to 17 Ϯ 1 FI/area (Fig. 5) . Treatment of the cells with either BVR or NT siRNA had no significant effect on the lowering of superoxide production by hemin and averaged 16 Ϯ 1 and 20 Ϯ 2 FI/area in ANG II ϩ NT ϩ hemin and ANG II ϩ BVR ϩ hemin, respectively (Fig. 5) . Consistent with experiments in Fig. 3 , treatment with BVR siRNA alone resulted in a significant increase in ANG II-mediated superoxide production, while treatment with NT siRNA had no effect on ANG II-dependent superoxide levels (Fig. 5) . The results indicate that reductions in bilirubin levels achieved via targeting of BVR with siRNA are not sufficient to attenuate the antioxidant effects of HO-1 induction in cultured mouse TALH cells.
Next, BVR activity was measured in TALH cells treated with hemin and BVR siRNA. BVR activity was not significantly altered by hemin treatment and averaged 1.8 Ϯ 0.13 vs. 1.5 Ϯ 0.11 units/ml in control vs. hemin-treated cells (Fig. 6) . BVR activity was not significantly altered by NT siRNA, but it was significantly decreased in cells transfected with BVR siRNA and treated with hemin and averaged 1.5 Ϯ 0.2 and 0.9 Ϯ 0.1 units/ml in NT vs. BVR siRNA (Fig. 6 ). These results demonstrate that BVR siRNA decreases BVR activity in hemin-treated cells, leading further support for the antioxidant actions of HO induction being mediated by CO in these cells.
BVR siRNA stimulates ANG II-mediated 86 Rb ϩ uptake in TALH cells. To determine the physiological significance of elevations in ANG II-mediated superoxide production by inhibiting BVR with siRNA, we examined ouabain-sensitive 86 Rb ϩ uptake as an index of sodium transport in TALH cells. Under control conditions, incubation of cells with ANG II at 10 Ϫ9 M had no effect on 86 Rb ϩ uptake (Fig. 7 ). This result is in agreement with a previous study examining the effect of ANG II on 86 Rb ϩ uptake in primary cultures of rat TALH cells (4). Pretreatment of TALH cells with nontargeting siRNA resulted in a significant decrease (P Ͻ 0.05) in 86 Rb ϩ uptake averaging 78 Ϯ 8% of control (Fig. 7) . In contrast, pretreatment of TALH cells with BVR siRNA resulted in a significant increase (P Ͻ 0.05) in 86 Rb ϩ uptake averaging 122 Ϯ 5% of control (Fig. 7) .
DISCUSSION
The production of CO and biliverdin are linked via the metabolism of heme by HO. Biliverdin is rapidly converted to bilirubin though the enzyme BVR. It has been very difficult to separate out the effect of bilirubin vs. CO in many of the effects mediated by increases in HO. The use of siRNA technology allows for separation of bilirubin generation from CO production as the critical enzyme for production of bilirubin can be targeted. This approach allowed us to determine the important role of bilirubin generation in buffering against ANG II-mediated superoxide production and to examine the physiological effects of decreased bilirubin generation on ANG-IImediated ouabain-sensitive Na ϩ transport in the TALH. The results of the present study highlight the important antioxidant properties of bilirubin in tubule cells exposed to ANG II. In both cultured mouse TALH and IMCD cells, reductions in cellular bilirubin formation by targeting BVR resulted in a significant enhancement of ANG II-mediated superoxide production. The effects of ANG II to increase superoxide and cause oxidative injury are consistent with previous studies by our laboratory and others. The results of the present study also reveal a potentially important role for HO-derived CO in acting 5 . Effect of HO-1 induction on superoxide production in TALH cells treated with BVR siRNA. Treatment with BVR siRNA increased ANG II-mediated superoxide production; however, treatment with BVR siRNA had no effect on the ability of HO-1 induction with heme to decrease ANG II-mediated superoxide production. *P Ͻ 0.05, significantly decreased compared with control. †P Ͻ 0.05, significantly increased compared with control. as an antioxidant to decrease ANG II-mediated superoxide production as induction of HO-1 with hemin was still able to attenuate ANG II-mediated superoxide production. However, the levels of bilirubin following hemin treatment were not measured in the present study; thus, it is possible that a slight increase in bilirubin may account for the observed actions of HO-1 induction. It is likely that the effects of CO on ANG II-mediated superoxide production are due to the effects of CO on NAD(P)H oxidase. Previous studies in smooth muscle cells have demonstrated that CO can interact with the heme moiety of NAD(P)H oxidase to reduce superoxide production (20) . The results of the present study support our previous observation that increases in CO levels using the carbon monoxidereleasing molecule, CORM-A1, prevents the increase in ANG II-mediated superoxide production in mTALH cells (9) . However, experiments in the present study were performed in unpolarized epithelial cells, which may exhibit a different phenotype compared with tubules in vivo.
Although our data establish that selective targeting of BVR with siRNA results in an augmentation of ANG II-mediated superoxide production, presumably through decreases in bilirubin production, it is possible that other mechanisms may be responsible for the enhancement of superoxide production upon inhibition of BVR. For example, it is possible that inhibition of BVR can have effects on important oxidant proteins such as NADPH oxidase, as previous studies have demonstrated that bilirubin can act directly to decrease the levels of this protein (11) . Another possibility is that inhibition of BVR can decrease the antioxidant capacity of the cell through decreases in the levels of proteins as SOD, catalase, thioredoxin reductase, and glutathione peroxidase. However, treatment of TALH cells with BVR siRNA had no effect on the levels of catalase, CuZn, and MnSOD proteins. Another possibility is that inhibition of BVR may have an effect on nitric oxide (NO) production in TALH cells. Several studies have demonstrated that NO can have inhibitory effects on superoxide production and superoxide can inhibit NO production (5, 15, 17) . Whether BVR regulates nitric oxide synthase isoforms or any other of the above-mentioned antioxidant proteins in TALH cells is not known but merits investigation in future studies.
Previous studies have demonstrated that biliverdin has important anti-oxidant effects equal to or greater than bilirubin (2, 19) . However, we found in our current study that inhibition of BVR resulted in a significant increase in ANG II-mediated superoxide production in both TALH and mIMCD3 cells. While we did observe that incubation of TALH cells with biliverdin resulted in an attenuation of ANG II-mediated superoxide production, this response was absent in cells that were treated with BVR siRNA. These results suggest that any increases in biliverdin levels following inhibition of BVR are not sufficient to decrease ANG II-mediated superoxide production in these cell types. Our results support a greater role for bilirubin in the protection against ANG II-mediated superoxide production in these cells. We did observe that induction of HO-1 was able to decrease ANG II-mediated superoxide production, even in the presence of inhibition of BVR. It is possible that induction of HO-1 is able to increase biliverdin levels high enough for biliverdin to act as an antioxidant under these conditions; however, further studies will be required to test this possibility.
BVR is not only an important enzyme for the conversion of biliverdin to bilirubin, but it can also act as a serine/threonine kinase capable of activating several intracellular secondary messenger pathways including 1) MAPK, 2) IGF/insulin receptor kinase, and 3) PKC (6, 12) . Further studies by Maines and colleagues (2, 10) have also demonstrated that BVR can act as a transcription factor binding to AP-1 and cyclic AMP response element sites. The importance of decreasing BVR vs. reducing bilirubin levels on ANG II-mediated superoxide production was not examined in the current study but warrants further investigation. In the TALH, several studies have demonstrated the importance of superoxide production in the regulation of tubular reabsorption and in maintaining vascular tone. Superoxide anion can regulate sodium reabsorption in the TALH, either directly or through limiting the bioavailability of nitric oxide (NO) (8, 17, 18) . In the present study, we found that inhibition of BVR resulted in an increase in ANG II-mediated superoxide production, which resulted in enhanced ANG II-dependent sodium transport in the cultured TALH cells. Similar to primary cultures of rat TALH cells, ANG II treatment at a concentration of 10 Ϫ9 M had little effect on basal 86 Rb ϩ uptake (4); however, this concentration of ANG II resulted in a significant enhancement of in 86 Rb ϩ uptake after treatment with BVR siRNA. Whether the effect of BVR siRNA to enhance sodium transport in the TALH was mediated specifically by a decrease in NO or an increase in superoxide was not determined and remains to be addressed. ANG II in the TALH, acting through NAD(P)H oxidase, has also been found to stimulate superoxide production and reduce NO levels leading to decreases in medullary blood and contributing to tissue injury in salt-sensitive hypertension (15, 16) . Induction of HO-1 in the medulla is able to significantly attenuate both increases in ANG II-mediated superoxide production and hypertension in the mouse (22, 23 and the development of salt-sensitive hypertension (13) . These results suggest an important role of HO in the TALH in the regulation of sodium reabsorption and the maintenance of blood pressure. However, the relative importance of CO vs. bilirubin production in mediating these effects in vivo needs to be examined in future studies.
The role of HO and its metabolites in the regulation of collecting duct function is largely unknown. HO-1 levels are enhanced by increases in tonicity in cultured mIMCD3 cells, and HO-1 has also been shown to be regulated by hypoxia in medullary interstitial cells (21, 25) . However, the function that HO or its metabolites plays in the regulation of sodium and water reabsorption in the inner medulla of the kidney has not been examined. The importance of HO-1 induction in the inner medulla to the regulation of blood pressure can be addressed in future studies using transgenic mice in which HO-1 is expressed specifically in collecting duct or interstitial cells.
In conclusion, decreases in BVR activity with specific siRNAs resulted in a significant increase in ANG II-mediated superoxide production in both mTALH and mIMCD3 cells, demonstrating the important antioxidant properties of bilirubin in tubular epithelial cells. Treatment of TALH cells with biliverdin resulted in a decrease in ANG II-mediated superoxide production in control cells but had no effect on the enhancement of superoxide production in cells treated with BVR siRNA. The increase in ANG II-mediated superoxide production was associated with an enhanced sodium transport in TALH cells. Induction of HO-1 was able to attenuate ANG II-mediated increases in superoxide production in cells treated with BVR siRNA. These results suggest that other pathways, including increases in CO or alterations in heme-containing proteins, such as NADPH oxidase, may be responsible for the significantly decreased ANG II-mediated superoxide production in tubular epithelial cells in response to HO-1 induction.
Perspectives and Significance
Several studies have demonstrated the antihypertensive actions of HO-1 induction in ANG II-dependent hypertension; however, the mechanism by which induction of HO-1 lowers blood pressure is not known. The results of the current study reveal an important role for bilirubin production in protecting renal tubular cells from ANG II-mediated increases in oxidative stress and sodium reabsorption. Taken together with previous studies, these results indicate that induction of HO-1 in the renal medulla may mediate the antihypertensive action of HO-1 induction through decreases in ANG II-mediated superoxide by mechanisms involving both bilirubin and CO, which ultimately results in increased natriuresis and lowering of blood pressure.
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